Skip to main content

Animations

Illustrated close up of DNA.

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
Sort by
Order
Filters
Sort by
Order
Sort by
Order
Results (357)
Sort by:
PSMF1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PSMF1, including 
  • -R231* (heterozygous and homozygous) - in development, est late 2025
  • -R242C (heterozygous and homozygous) - in development, est late 2025
  • -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.  
  • PSMF1
OMP25 Edited Mito-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged OMP25 for Mito-IP.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: late 2026
  • OMP25
EEA1 Edited Endo-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged EEA1 for Endo-IP.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: late 2026
  • EEA1
TMEM192 Edited Lyso-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged TMEM192 for Lyso-IP.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: late 2026
  • TMEM192
Human O-GlcNAc T72 aSyn ELISA
Assay
ELISA kit for quantification of alpha-synuclein with O-GlcNAc on Threonine72 (O-GlcNAc T72 aSyn).This assay development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated availability: Late 2027
  • Alpha-Synuclein
Human pS106 Rab12 ELISA
Assay
ELISA kit for quantification of Rab12 phosphorylated at Serine106 (pS106 Rab12).Estimated availability: Late 2026
  • Rab
Human pS111 Rab13 ELISA
Assay
ELISA kit for quantification of Rab13 phosphorylated at Serine111 (pS111 Rab13)Estimated availability: Late 2027
  • Rab
Human Rab13 ELISA
Assay
ELISA kit for quantification of Rab13.Estimated availability: Late 2027
  • Rab
Alpha-Synuclein Aggregation Assay in Immortalized Neurons
Assay
High-throughput in vitro assay to detect alpha-synuclein aggregation developed in a dopamine neuron-like cell line of human origin. Available as a fee-for-service assay.  Generated as part of the Industry Tools Consortium.
  • Alpha-Synuclein
Alpha-Synuclein Aggregation Assay in iPSC-derived Triculture
Assay
High-throughput in vitro assay to detect alpha-synuclein aggregation in iPSC-derived neuron and glial tri-culture system treated with alpha-synuclein pre-formed fibrils. Available as a fee-for-service assay. Estimated Availability: Late 2027
  • Alpha-Synuclein
Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 

"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.